New class viral immunotherapy distinguished by greater efficacy and safety
Vaxalto’s technology is based on exceptional immunologic synergy between an APMV oncolytic virus and a novel immunomodulator
A multimodal approach to lasting cancer eradicationVaxalto’s innovative therapeutics attack cancer at multiple points of intervention. Our patent-pending APMV oncolytic virus triggers direct tumor cell-killing, exposing tumor antigens and activating the immune system to seek and destroy cancer cells. This effect is enhanced by a new class immunomodulator engineered into the virus, which activates vascular and immune cells in the tumor microenvironment and further drives tumor rejection. A biomarker of response predicts where the therapy is most likely to work, further enhancing efficacy. The therapy also prompts long-term immunological memory to mitigate any return of the cancer cells.
Viral Immunotherapy Mechanism of Action
Systemic Therapeutic Effects
- Viral construct is injected directly into the tumor
- Anti-tumor immunity is activated systemically
- Immune cells attack and eliminate primary tumor as well as metastases in different organs
The science that sets us apart
Pre-clinical studies with unprecedented results
Vaxalto’s engineered avian paramyxovirus (APMV) oncolytic virus shows exceptionally high therapeutic impact. In preclinical studies, intratumoral administration of the viral construct led to complete tumor eradication and yielded an unprecedented 100% survival rate in mouse models of melanoma and breast cancer as a single agent therapy.
Technology distinguished by improved safety
Our technology poses very low risk of side-effects because APMV is not a human pathogen. As a single-strand RNA virus (ssRNA), it selectively infects tumor cells without integrating into the host genome, which further reduces patient risk. Intratumoral administration of the therapy enhances safety by eliminating systemic exposure to the virus and reducing potential for systemic toxicity.
Powerful and versatile therapeutic platform
Our lead candidate—consisting of an APMV viral backbone and a proprietary immunomodulator—has been designed to re-program the tumor immune microenvironment by activating vascular and immune cells, in addition to direct tumor cell killing. This multi-modal therapeutic approach potently primes the body to seek and destroy cancer cells, driving system-wide elimination of metastases and providing long-term immunological memory to mitigate cancer relapse. In addition, the viral platform can be engineered using different gene candidates, giving it the potential to expand treatment indications, from multiple forms of cancer to development of vaccines for emerging pathogens.